Detail akcie Adial Phrmctcls Rg online

Business Summary: Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Adial Pharmaceuticals Inc revenues was not reported. Net loss decreased 46% to $6M. Lower net loss reflects Inducement expense decrease from $4.5M (expense) to $0K, Research and development expenses - decrease of 19% to $2M (expense), Other income (expenses) increase from $0K to $165K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$78.90 to -$15.15.